Most IND delays are not caused by a single catastrophic problem.
More often, delays emerge from a combination of unresolved gaps, incomplete evidence, documentation deficiencies, and readiness issues that accumulate over time.
Scientific progress may be advancing.
Development milestones may be on track.
Yet organizations frequently discover late in the process that critical readiness questions remain unanswered.
Understanding the most common causes of delay can help teams identify risks earlier and improve overall submission preparedness.
Why IND Delays Occur
Preparing for an IND submission requires coordination across multiple functions.
These may include:
- Regulatory affairs
- Clinical development
- CMC teams
- Manufacturing
- Quality
- External partners
Each function contributes information required to support submission readiness.
Delays often occur when information, evidence, and expectations become disconnected.
Reason 1: Missing Evidence for Regulatory Expectations
One of the most common readiness issues involves incomplete evidence coverage.
Organizations may understand regulatory expectations but lack sufficient supporting evidence.
Examples include:
- Incomplete studies
- Missing supporting analyses
- Unavailable documentation
- Outstanding validation activities
The challenge is often visibility.
Teams may not realize evidence gaps exist until readiness reviews begin.
Reason 2: Limited Traceability Between Expectations and Evidence
Even when evidence exists, organizations frequently struggle to demonstrate how that evidence supports specific expectations.
Questions often arise such as:
- Which expectation does this evidence support?
- Is supporting evidence complete?
- Have all critical expectations been addressed?
Without traceability, readiness assessments become heavily dependent on manual reviews.
Reason 3: CMC Readiness Challenges
Chemistry, Manufacturing, and Controls activities remain a frequent source of delay.
Common issues include:
- Incomplete manufacturing documentation
- Analytical method readiness concerns
- Process development gaps
- Insufficient supporting evidence
- Quality-related deficiencies
CMC readiness often becomes more difficult to assess as programs grow in complexity.
Reason 4: Fragmented Information Across Systems
Evidence is rarely stored in a single location.
Organizations often manage information across:
- Scientific platforms
- Laboratory systems
- Quality systems
- Shared repositories
- Regulatory documentation tools
Fragmentation makes it difficult to establish a unified view of readiness.
Reason 5: Readiness Assessments Occur Too Late
Many organizations evaluate readiness only when major milestones approach.
While milestone reviews are important, late-stage assessments can create challenges.
Issues discovered close to submission deadlines often require:
- Additional studies
- New documentation
- Process revisions
- Cross-functional coordination
Earlier visibility allows teams to address problems before they become critical.
Reason 6: Regulatory Expectations Continue to Evolve
Regulatory expectations are not static.
Organizations must continuously evaluate:
- New guidance
- Updated expectations
- Industry practices
- Agency feedback trends
Programs that rely on outdated assumptions may encounter readiness issues later in development.
Reason 7: Unclear Ownership and Accountability
Readiness activities often involve multiple teams.
Without clearly defined ownership, organizations may encounter:
- Duplicate work
- Unresolved issues
- Delayed decisions
- Inconsistent documentation
Successful programs typically establish clear accountability for readiness activities.
Reason 8: Overreliance on Spreadsheets
Many organizations continue to manage readiness using spreadsheets.
While spreadsheets can be useful, they often struggle to support:
- Evidence traceability
- Gap tracking
- Cross-functional collaboration
- Continuous readiness monitoring
As programs grow, maintaining an accurate readiness picture becomes increasingly difficult.
A Better Approach to Readiness Management
Organizations can reduce delay risk by focusing on four core activities.
Understand Expectations
Identify applicable regulatory expectations early.
Map Supporting Evidence
Connect available evidence directly to expectations.
Track Gaps Continuously
Maintain visibility into unresolved readiness issues.
Monitor Readiness Over Time
Treat readiness as a continuous process rather than a one-time review.
Together, these activities help organizations identify issues earlier and improve decision-making.
Indicators of a Mature Readiness Program
Organizations with mature readiness capabilities often demonstrate:
- Expectation management processes
- Evidence traceability
- Continuous gap tracking
- Cross-functional visibility
- Structured readiness assessments
- Ongoing readiness monitoring
These capabilities help reduce uncertainty throughout development.
Related Resources
- IND Readiness Guide: Preparing for Successful Investigational New Drug Submissions
- Why IND Readiness Is Still Broken
- Evidence Traceability for IND Readiness
- CMC Documentation Readiness Framework
About BeaconOS
BeaconOS helps biopharma organizations improve readiness visibility by connecting regulatory expectations, available evidence, identified gaps, and readiness decisions.
By helping teams continuously assess readiness rather than relying solely on milestone reviews, BeaconOS supports more informed submission planning and regulatory decision-making.